DiaMedica Therapeutics (DMAC) Projected to Post Quarterly Earnings on Tuesday

DiaMedica Therapeutics (NASDAQ:DMAC) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

DMAC opened at $3.76 on Friday. The firm’s 50-day simple moving average is $4.31 and its 200-day simple moving average is $5.01. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.82. The firm has a market cap of $161.14 million, a price-to-earnings ratio of -6.71 and a beta of 1.29.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price objective on DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 19th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.